2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2387

Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2488

MDA Versus DAPSA: Applicability in a Real World

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 1970

Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2208

Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2605

Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2611

Mesenchymal Stem Cells in Scleroderma: A Systematic Review

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2543

Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2020

Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1946

Metabolic Regulation in Cybrids Obtained from Healthy and Osteoarthritic (OA) Patients: Impaired Metabolic Flexibility in OA Process

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2324

Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2377

Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2357

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2015

Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2240

Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].